Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: Overcoming local anti-human adenovirus immunity for potent TB protection

Mucosal Immunology

Volumn 8, Issue 6, 2015, Pages 1373-1387

  Jeyanathan, M ^a   Thanthrige Don, N ^a   Afkhami, S ^a   Lai, R ^a   Damjanovic, D ^a   Zganiacz, A ^a   Feng, X ^a   Yao, X D ^a   Rosenthal, K L ^a   Fe Medina, M ^a   Gauldie, J ^a   Ertl, H C ^b   Xing, Z ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BCG VACCINE; BACTERIUM ANTIBODY; NEUTRALIZING ANTIBODY;

ADENOVIRIDAE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; CELLULAR IMMUNITY; CHIMPANZEE; CHIMPANZEE ADENOVIRUS 68; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN ADENOVIRUS 5; IMMUNOGENICITY; IMMUNOPATHOLOGY; LUNG TUBERCULOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE VECTOR; HUMAN; IMMUNOLOGY; PAN TROGLODYTES;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; PAN TROGLODYTES; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 84945174778     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2015.29     Document Type: Article

References (65)

1. Cooper A.M. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 27, 393-422 (2009
2. Kaufmann S.H. Tuberculosis vaccine development: strength lies in tenacity. Trends Immunol. 33, 373-379 (2012
3. McShane H., et al. BCG: myths, realities, and the need for alternative vaccine strategies. Tuberculosis (Edinb) 92, 283-288 (2012
4. Brennan M.J., Stone M.R., & Evans T. A rational vaccine pipeline for tuberculosis. Int. J. Tuberc. Lung Dis. 16, 1566-1573 (2012
5. Behr M.A. BCG-different strains, different vaccines?. Lancet Infect. Dis. 2, 86-92 (2002
6. Xing Z., Jeyanathan M., & Smaill F. New approaches to TB vaccination. Chest 146, 804-812 (2014
7. Urdahl K.B., Shafiani S., & Ernst J.D. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol. 4, 288-293 (2011
8. Horvath C.N., Shaler C.R., Jeyanathan M., Zganiacz A., & Xing Z. Mechanisms of delayed anti-tuberculosis protection in the lung of parenteral BCG-vaccinated hosts: a critical role of airway luminal T cells. Mucosal. Immunol. 5, 420-431 (2012
9. Jeyanathan M., et al. Pulmonary M. tuberculosis infection delays Th1 immunity via immunoadaptor DAP12-regulated IRAK-M and IL-10 expression in antigen-presenting cells. Mucosal Immunol. 7, 670-683 (2014
10. Chen K., & Kolls J.K. T cell-mediated host immune defenses in the lung. Annu. Rev. Immunol. 31, 605-633 (2013
11. Beverley P.C., Sridhar S., Lalvani A., & Tchilian E.Z. Harnessing local and systemic immunity for vaccines against tuberculosis. Mucosal Immunol. 7, 20-26 (2014
12. Jeyanathan M., Heriazon A., & Xing Z. Airway luminal Tcells: a newcomer on the stage of TB vaccination strategies. Trends Immunol. 31, 247-252 (2010
13. Belyakov I.M., & Ahlers J.D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?. J. Immunol. 183, 6883-6892 (2009
14. Griffiths K.L., & Khader S.A. Novel vaccine approaches for protection against intracellular pathogens. Curr. Opin. Immunol. 28C, 58-63 (2014
15. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12, 592-605 (2012
16. Baaten B.J., Cooper A.M., Swain S.L., & Bradley L.M. Location, location, location: the impact of migratory heterogeneity on T cell function. Front Immunol 4, 311 (2013
17. Andersen P., & Kaufmann S.H. Novel vaccination strategies against tuberculosis. Cold Spring Harb. Perspect. Med. 4, 210-216 (2014
18. Lewis D.J., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4, e6999 (2009
19. Tameris M.D., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021-1028 (2013
20. Aerosol Vaccines For Tuberculosis Workshop Summary Group: Developing Aerosol Vaccines for Mycobacterium tuberculosis. Vaccine, 2015 (in press
21. Xing Z., & Lichty B.D. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) 86, 211-217 (2006
22. Rollier C.S., Reyes-Sandoval A., Cottingham M.G., Ewer K., & Hill A.V. Viral vectors as vaccine platforms: deployment in sight. Curr. Opin. Immunol. 23, 377-382 (2011
23. Song K., et al. Genetic immunization in the lung induces potent local and systemic immune responses. Proc. Natl. Acad. Sci. USA 107, 22213-22218 (2010
24. Lasaro M.O., & Ertl H.C. New insights on adenovirus as vaccine vectors. Mol. Ther. 17, 1333-1339 (2009
25. Majhen D., et al. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum. Gene Ther. 25, 301-317 (2014
26. + cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat. Med. 17, 1128-1131 (2011
27. Smaill F., et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting antiadenovirus immunity. Sci. Transl. Med. 5, 205ra134 (2013
28. Kaufmann S.H., Juliana McElrath M., Lewis D.J., & Del Giudice G. Challenges and responses in human vaccine development. Curr. Opin. Immunol. 28C, 18-26 (2014
29. Xiang Z., et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis. 12, 1596-1599 (2006
30. Frahm N., et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J. Clin. Invest. 122, 359-367 (2012
31. +) T-cell responses but is attenuated by preexisting Ad5 immunity. Proc. Natl. Acad. Sci. USA 109, E3503-E3512 (2012
32. Fauci A.S., Marovich M.A., Dieffenbach C.W., Hunter E., & Buchbinder S.P. Immunology. Immune activation with HIV vaccines. Science 344, 49-51 (2014
33. Colloca S., et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 4, 115ra112 (2012
34. + T cells following human-, simian-, and chimpanzeederived recombinant adenoviral vector immunization. J. Immunol. 190, 2720-2735 (2013
35. Capone S., et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev. Vaccines 12, 379-393 (2013
36. Barnes E., et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci. Transl. Med. 4, 115ra111 (2012
37. + T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat. Commun. 4, 2836 (2013
38. Fitzgerald J.C., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170, 1416-1422 (2003
39. Kobinger G.P., et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346, 394-401 (2006
40. Zhou D., et al. An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat. Protoc. 5, 1775-1785 (2010
41. Wang J., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173, 6357-6365 (2004
42. Jeyanathan M., et al. Differentially imprinted innate immunity by mucosal boost vaccination determines antituberculosis immune protective outcomes, independent of T-cell immunity. Mucosal Immunol. 6, 612-625 (2013
43. Teles R.M., et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 339, 1448-1453 (2013
44. Antonelli L.R., et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J. Clin. Invest. 120, 1674-1682 (2010
45. Santosuosso M., Zhang X., McCormick S., Wang J., Hitt M., & Xing Z. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 Tcells within the airway lumen. J. Immunol. 174, 7986-7994 (2005
46. D'souza S., Rosseels V., Romano M., Tanghe A., Denis O., & Jurion F., et al. Mapping of murine Th1 helper T-cell epitopes ofmycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect. Immun. 71, 483-493 (2003
47. Hoffmeister B., Kiecker F., Tesfa L., Volk H.D., Picker L.J., & Kern F. Mapping T cell epitopes by flow cytometry. Methods 29, 270-281 (2003
48. McCoy K., et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human-or chimpanzee-derived adenovirus vectors. J. Virol. 81, 6594-6604 (2007
49. +) Tcells is crucial to inhibit the growth of mucosal tumors. Sci. Transl. Med. 5, 172ra120 (2013
50. Santosuosso M., McCormick S., Zhang X., Zganiacz A., & Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun. 74, 4634-4643 (2006
51. Dean G., et al. Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines. Vaccine 32, 1304-1310 (2014
52. Xing Z., McFarland C.T., Sallenave J.M., Izzo A., Wang J., & McMurray D.N. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One 4, e5856 (2009
53. Duerr A., et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J. Infect. Dis. 206, 258-266 (2012
54. Perreau M., Pantaleo G., & Kremer E.J. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J. Exp. Med. 205, 2717-2725 (2008
55. Launois P., et al. T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect. Immun. 62, 3679-3687 (1994
56. Cohen C.J., Xiang Z.Q., Gao G.P., Ertl H.C., Wilson J.M., & Bergelson J.M. Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J. Gen. Virol. 83, 151-155 (2002
57. Bennekov T., Dietrich J., Rosenkrands I., Stryhn A., Doherty T.M., & Andersen P. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur. J. Immunol. 36, 3346-3355 (2006
58. Tchilian E., Ahuja D., Hey A., Jiang S., & Beverley P. Immunization with different formulations of Mycobacterium tuberculosis antigen 85A induces immune responses with different specificity and protective efficacy. Vaccine 31, 4624-4631 (2013
59. Goonetilleke N., & McMichael A.J. Immunology. Antigen processing takes a new direction. Science 340, 937-938 (2013
60. + T cell epitope recognition paradigms. Science 340, 1237874 (2013
61. Choi J.H., Schafer S.C., Zhang L., Juelich T., Freiberg A.N., & Croyle M.A. Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine. Mol. Pharm. 10, 3342-3355 (2013
62. Richardson J.S., Abou M.C., Tran K.N., Kumar A., Sahai B.M., & Kobinger G.P. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs. J. Infect. Dis. 204, S1032-S1042 (2011
63. Hutnick N.A., Carnathan D., Demers K., Makedonas G., Ertl H.C., & Betts M.R. Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. Vaccine 28, 1932-1941 (2010
64. Xing Z., et al. Recent advances in the development of adenovirus-and poxvirus-vectored tuberculosis vaccines. Curr. Gene Ther. 5, 485-492 (2005
65. Xing Z., Zganiacz A., Wang J., Divangahi M., & Nawaz F. IL-12-independent Th1-type immune responses to respiratory viral infection: requirement of IL-18 for IFN-gamma release in the lung but not for the differentiation of viral-reactive Th1-type lymphocytes. J. Immunol. 164, 2575-2584 (2000